TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics- Joint venture to focus on the Nodal protein, a previously untargeted and critical mediator of aggressive cancer progression and treatment resistance
2018/10/23 TaiRx, Inc [...]
A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.
2018/4/15 TaiRx’s CVM-1118 [...]
TaiRx published study results of serum GPx-3 protein levels and associated bioactivity in healthy subjects and sepsis patients in Clinica Chimica Acta.
2017/10/31 Lee WJ, Chen YL, Chu YW, Chien [...]